Fundamental, Research, Video

Life Science Tools and Services: Time to Be Selective Amid a Challenging H2 2023

Sel Hardy, Vice President of Equity Reseach
09 October 2023

During Q2, several companies operating in the Life Science Tools and Services (LSTS) industry encountered obstacles due to the economic downturn in China and the restrained spending habits of biopharma clients in Europe and the US. These factors have the potential to continue impacting revenue and margins. Nevertheless, the industry still offers hopeful prospects despite its lower performance compared to the broader market. In this recording, CFRA Research Vice President of Equity Research Sel Hardy sheds light on the challenging business climate, existing challenges and potential benefits, and the winners and losers in the life science sector.


Want to learn more? Download the slide deck.

Solutions

Fundamental Equity Research
Gain a comprehensive view of global themes, industries, and companies.

Related Insights

Life Science Tools and Services: Time to Be Selective Amid a Challenging H2 2023

Life Science Tools and Services: Time to Be Selective Amid a Challenging H2 2023

Several Life Science Tools and Services (LSTS) companies had a tough Q2, negatively...
Read more